ADA: AZ’s oral GLP‑1 shows competitive efficacy in phase 2, setting stage for pivotal program on June 09, 2026 Adangme language AstraZeneca AZD5004 cardiometabolic Clinical Trials Diabetes Mellitus, Non-Insulin-Dependent elecoglipron Glycosylated hemoglobin A Obesity risk factors SOLSTICE VISTA trial Weight Loss +